


## NC-III-49-1

Cat. No.:	HY-150683
CAS No.:	3031654-46-0
Molecular Formula:	C <sub>44</sub> H <sub>50</sub> N <sub>4</sub> O <sub>11</sub> S <sub>2</sub>
Molecular Weight:	875.02
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. NC-III-49-1 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with K <sub>d</sub> values of 0.095, 0.32, 0.29, 0.089, 5.5, 0.058 nM, respectively. NC-III-49-1 shows antiproliferative activity. NC-III-49-1 decreases the expression of c-Myc <sup>[1]</sup> .			
IC <sub>50</sub> & Target	BRD4-1 0.095 nM (Kd)	BRD4-2 0.032 nM (Kd)	BRD4-T 0.29 nM (Kd)	BRDT-1 0.089 nM (Kd)
	BRDT-2 5.5 nM (Kd)	BRDT-T 0.058 nM (Kd)		
In Vitro	NC-III-49-1 (0-10 μM; 72 h) shows antiproliferative activity with an IC <sub>50</sub> value of 0.69 nM in MM1.S cells <sup>[1]</sup> . NC-III-49-1 (0-10 μM; 6 h) decreases the expression of c-Myc in a dose dependent manner <sup>[1]</sup> . .NC-III-49-1 shows inhibition by interact with both KAc sites <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <sup>[1]</sup>			
	Cell Line:		MM1.S cells	
	Concentration:		0-10 μM	
	Incubation Time:		72 h	
	Result:		Showed subnanomolar growth inhibition with an IC <sub>50</sub> value of 0.69 nM in multiple myeloma MM1.S cells.	
	Western Blot Analysis <sup>[1]</sup>			
	Cell Line:		MM1.S cells	
	Concentration:		0-10 μM	
	Incubation Time:		6 h	
	Result:		Decreased the expression of c-Myc in a dose dependent manner.	

#### In Vivo

NC-III-49-1 shows metabolic stability in human and mouse liver microsomes with an  $T_{1/2}$  values of <2.3, <2.3 min, respectively<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Guan X, et al. Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity. J Med Chem. 2022 Jul 22.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA